Literature DB >> 22929726

Electroencephalographic and hypnotic recoveries after brief and prolonged infusions of etomidate and optimized soft etomidate analogs.

Rile Ge1, Ervin Pejo, S Shaukat Husain, Joseph F Cotten, Douglas E Raines.   

Abstract

BACKGROUND: Methoxycarbonyl etomidate is the prototypical soft etomidate analog. Because it has relatively low potency and is extremely rapidly metabolized, large quantities must be infused to maintain hypnosis. Consequently with prolonged infusion, metabolite reaches sufficient concentrations to delay recovery. Dimethyl-methoxycarbonyl metomidate (DMMM) and cyclopropyl-methoxycarbonyl metomidate (CPMM) are methoxycarbonyl etomidate analogs with higher potencies and slower clearance. Because of these properties, we hypothesized that dosing would be lower and electroencephalographic and hypnotic recoveries would be faster - and less context-sensitive - with DMMM or CPMM versus methoxycarbonyl etomidate or etomidate.
METHODS: Etomidate, DMMM, and CPMM where infused into rats (n = 6 per group) for either 5 min or 120 min. After infusion termination, electroencephalographic and hypnotic recovery times were measured. The immobilizing ED50 infusion rates were determined using a tail clamp assay.
RESULTS: Upon terminating 5-min infusions, electroencephalographic and hypnotic recovery times were not different among hypnotics. However, upon terminating 120-min infusions, recovery times varied significantly with respective values (mean ± SD) 48 ± 13 min and 31 ± 6.5 min (etomidate), 17 ± 7.0 min and 14 ± 3.4 min (DMMM), and 4.5 ± 1.1 min and 4.2 ± 1.6 min (CPMM). The immobilizing ED50 infusion rates were (mean ± SD) 0.19 ± 0.03 mg · kg · min (etomidate), 0.60 ± 0.12 mg · kg · min (DMMM), and 0.89 ± 0.18 mg · kg · min (CPMM).
CONCLUSIONS: Electroencephalographic and hypnotic recoveries following prolonged infusions of DMMM and CPMM are faster than those following methoxycarbonyl etomidate or etomidate. In the case of CPMM infusion, recovery times are 4 min and context-insensitive.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22929726      PMCID: PMC3509380          DOI: 10.1097/ALN.0b013e31826d3de2

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  15 in total

Review 1.  Soft drug design: general principles and recent applications.

Authors:  N Bodor; P Buchwald
Journal:  Med Res Rev       Date:  2000-01       Impact factor: 12.944

2.  Blockade of acetylcholine receptors does not change the dose of etomidate required to produce immobility in rats.

Authors:  Yi Zhang; Michael J Laster; Edmond I Eger; Manohar Sharma; James M Sonner
Journal:  Anesth Analg       Date:  2007-04       Impact factor: 5.108

3.  A general approach to modeling biphasic relationships.

Authors:  William N Beckon; Cary Parkins; Alexey Maximovich; Angela V Beckon
Journal:  Environ Sci Technol       Date:  2008-02-15       Impact factor: 9.028

4.  I.v. anaesthesia and EEG burst suppression in rats: bolus injections and closed-loop infusions.

Authors:  P C Vijn; J R Sneyd
Journal:  Br J Anaesth       Date:  1998-09       Impact factor: 9.166

5.  Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.

Authors:  Joseph F Cotten; S Shaukat Husain; Stuart A Forman; Keith W Miller; Elizabeth W Kelly; Hieu H Nguyen; Douglas E Raines
Journal:  Anesthesiology       Date:  2009-08       Impact factor: 7.892

6.  Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action.

Authors:  S Shaukat Husain; Ervin Pejo; Rile Ge; Douglas E Raines
Journal:  Anesthesiology       Date:  2012-11       Impact factor: 7.892

7.  An effective correlation dimension and burst suppression ratio of the EEG in rat. Correlation with sevoflurane induced anaesthetic depth.

Authors:  P L C van den Broek; C M van Rijn; J van Egmond; A M L Coenen; L H D J Booij
Journal:  Eur J Anaesthesiol       Date:  2006-02-10       Impact factor: 4.330

8.  No correlation between quantitative electroencephalographic measurements and movement response to noxious stimuli during isoflurane anesthesia in rats.

Authors:  I J Rampil; M J Laster
Journal:  Anesthesiology       Date:  1992-11       Impact factor: 7.892

9.  Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery.

Authors:  C L Westmoreland; J F Hoke; P S Sebel; C C Hug; K T Muir
Journal:  Anesthesiology       Date:  1993-11       Impact factor: 7.892

10.  The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers.

Authors:  T D Egan; H J Lemmens; P Fiset; D J Hermann; K T Muir; D R Stanski; S L Shafer
Journal:  Anesthesiology       Date:  1993-11       Impact factor: 7.892

View more
  10 in total

Review 1.  The Role of GABA Receptor Agonists in Anesthesia and Sedation.

Authors:  Janette Brohan; Basavana G Goudra
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

Review 2.  Pharmacologic Considerations for Pediatric Sedation and Anesthesia Outside the Operating Room: A Review for Anesthesia and Non-Anesthesia Providers.

Authors:  Narjeet Khurmi; Perene Patel; Molly Kraus; Terrence Trentman
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

3.  Analogues of etomidate: modifications around etomidate's chiral carbon and the impact on in vitro and in vivo pharmacology.

Authors:  Ervin Pejo; Peter Santer; Spencer Jeffrey; Hilary Gallin; S Shaukat Husain; Douglas E Raines
Journal:  Anesthesiology       Date:  2014-08       Impact factor: 7.892

4.  Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs.

Authors:  Jason A Campagna; Kevin Pojasek; David Grayzel; John Randle; Douglas E Raines
Journal:  Anesthesiology       Date:  2014-12       Impact factor: 7.892

5.  Distinct Hypnotic Recoveries After Infusions of Methoxycarbonyl Etomidate and Cyclopropyl Methoxycarbonyl Metomidate: The Role of the Metabolite.

Authors:  Ervin Pejo; Jifeng Liu; Xiangjie Lin; Douglas E Raines
Journal:  Anesth Analg       Date:  2016-04       Impact factor: 5.108

6.  Anesthetic drug development: Novel drugs and new approaches.

Authors:  Hovig V Chitilian; Roderic G Eckenhoff; Douglas E Raines
Journal:  Surg Neurol Int       Date:  2013-03-19

7.  Adrenocortical suppression and recovery after continuous hypnotic infusion: etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate.

Authors:  Rile Ge; Ervin Pejo; Joseph F Cotten; Douglas E Raines
Journal:  Crit Care       Date:  2013-01-30       Impact factor: 9.097

Review 8.  Etomidate derivatives: Novel pharmaceutical agents in anesthesia.

Authors:  Raymond J Malapero; Michael P Zaccagnino; Ethan Y Brovman; Alan David Kaye; Richard D Urman
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2017 Oct-Dec

9.  Minimum infusion rate and adrenocortical function after continuous infusion of the novel etomidate analog ET-26-HCl in rats.

Authors:  Junli Jiang; Bin Wang; Zhaoqiong Zhu; Jun Yang; Jin Liu; Wensheng Zhang
Journal:  PeerJ       Date:  2017-09-04       Impact factor: 2.984

Review 10.  Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics.

Authors:  Beatrijs I Valk; Michel M R F Struys
Journal:  Clin Pharmacokinet       Date:  2021-06-01       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.